Prescient Therapeutics Limited

ASX:PTX.AX

0.04 (AUD) • At close September 16, 2024
Bedrijfsnaam Prescient Therapeutics Limited
Symbool PTX.AX
Munteenheid AUD
Prijs 0.041
Beurswaarde 33,018,120
Dividendpercentage 0%
52-weken bereik 0.037 - 0.105
Industrie Biotechnology
Sector Healthcare
CEO Mr. Steven Lee Yatomi-Clarke
Website https://ptxtherapeutics.com

An error occurred while fetching data.

Over Prescient Therapeutics Limited

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent

Vergelijkbare Aandelen

Kazia Therapeutics Limited logo

Kazia Therapeutics Limited

KZA.AX

0.08 AUD

Cann Group Limited logo

Cann Group Limited

CAN.AX

0.038 AUD

Proteomics International Laboratories Limited logo

Proteomics International Laboratories Limited

PIQ.AX

0.6 AUD

Vita Life Sciences Limited logo

Vita Life Sciences Limited

VLS.AX

2.15 AUD

SomnoMed Limited logo

SomnoMed Limited

SOM.AX

0.44 AUD

SDI Limited logo

SDI Limited

SDI.AX

0.98 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)